Insulin glargine (Toujeo) vs SHR-3167
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
Insulin glargine (Toujeo)
Marketed by Sanofi
NCT01499082 · Phase 3 · completed
The trial was large and randomized, with an active insulin glargine comparator, and its primary HbA1c endpoint was a hard clinical treatment measure that met the prespecified non-inferiority margin. However, treatment was open-label rather than double-blinded, so the evidence is considered moderate despite the favorable non-inferiority result.
Reported efficacy
Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): HOE901-U300 -0.83 percentage of hemoglobin (Standard Error 0.06) | Lantus -0.83 percentage of hemoglobin (Standard Error 0.061) (met)
Result source: NCT01499082
SHR-3167
Developed by Jiangsu Hengrui Pharmaceuticals
NCT06688123 · Phase 2 · completed
The study randomized 275 adults with type 2 diabetes to once-weekly SHR-3167 (two titration schemes) or daily insulin glargine in an open-label, treat-to-target design. Its primary endpoint was change in HbA1c at week 20, a regulator-accepted measure in type 2 diabetes. Hengrui reports HbA1c reductions similar to glargine (differences -0.02% and -0.14%, with both confidence intervals crossing zero), but neither the registry nor the company states a non-inferiority margin, so whether the primary comparison was met cannot be called. The figures are company-reported and not peer reviewed.
Company release of an EASD 2026 late-breaking abstract; not peer reviewed and not posted on the registry.
Next expected readout: December 2026 · NCT07472725 (registry estimate)
Reported efficacy
Change from baseline to week 20 in HbA1c (HemoglobinA1c) (Week 0 to week 20.): Change in HbA1c from baseline to week 20 (primary): least-squares mean -1.37% (SHR-3167 group A, titration step 2 mg) and -1.49% (group B, titration step 1.5 mg) vs -1.35% with insulin glargine U100; differences -0.02% (95% CI -0.20 to 0.16) and -0.14% (95% CI -0.32 to 0.05); 275 randomized. No non-inferiority margin is stated.
Result source: NCT06688123
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Insulin glargine (Toujeo) | SHR-3167 |
|---|---|---|
| HbA1c, change | —Not reported | —Trial running · NCT07913061 |
| Body weight, change (kg) | —Not reported | —Trial running · NCT07913061 |
| HbA1c below 7% | —Not reported | —Trial running · NCT07913061 |
| Fasting plasma glucose, change | —Not reported | —Trial running · NCT07913061 |
| 3-point MACE (% with event) | —Not reported | —Trial running · NCT07913061 |
HbA1c, change
- Insulin glargine (Toujeo)
- —Not reported
- SHR-3167
- —Trial running · NCT07913061
Body weight, change (kg)
- Insulin glargine (Toujeo)
- —Not reported
- SHR-3167
- —Trial running · NCT07913061
HbA1c below 7%
- Insulin glargine (Toujeo)
- —Not reported
- SHR-3167
- —Trial running · NCT07913061
Fasting plasma glucose, change
- Insulin glargine (Toujeo)
- —Not reported
- SHR-3167
- —Trial running · NCT07913061
3-point MACE (% with event)
- Insulin glargine (Toujeo)
- —Not reported
- SHR-3167
- —Trial running · NCT07913061
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Insulin glargine (Toujeo): 4 of 4 rows · SHR-3167: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Insulin glargine (Toujeo) |
|---|---|
| Dropout rate | 14.8%a NCT03013985 · Phase 4 · registry result, not featured evidence show 1 more result14.9% NCT02451137 · Phase 4 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT03013985 · Phase 4 · registry result, not featured evidence show 1 more result2.6% NCT02451137 · Phase 4 · registry result, not featured evidence |
| Serious AEs | 19.4%a NCT03013985 · Phase 4 · registry result, not featured evidence show 1 more result9.8% NCT02451137 · Phase 4 · registry result, not featured evidence |
| Most frequent reported AEs | a trauma 3.7% cough 0.9% gastroparesis 0.9% NCT03013985 · Phase 4 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Insulin glargine (Toujeo)
show 6 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin glargine (Toujeo)'s landscape · SHR-3167's landscape